



Importance of the directionality of the glycosaminoglycan chain on the interaction with FGF-1

Journal:	<i>Glycobiology</i>
Manuscript ID:	GLYCO-2014-00014.R1
Manuscript Type:	Communications
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Nieto, Pedro; Instituto de Investigaciones Químicas, Química Bio-orgánica Muñoz-García, Juan Carlos; CSIC, Instituto de Investigaciones Químicas, Química Bioorgánica, Glycosystems Lab.</p> <p>Carrero, Paula; CSIC, Instituto de Investigaciones Químicas, Química Bioorgánica, Glycosystems Lab.</p> <p>Canales, Angeles; CSIC, CIB, Dept. of Chemical & Physical Biology</p> <p>JIMENEZ-BARBERO, JESUS; CSIC, CIB, Dept. of Chemical & Physical Biology</p> <p>Martin-Lomas, Manuel; cicBiomagune, Biofunctional Nanomaterials Unit</p> <p>Imberty, Anne; CERMAV-CNRS, Molecular Glycobiology</p> <p>de Paz, Jose Luis; Instituto de Investigaciones Químicas, Química Bio-orgánica</p> <p>Angulo, Jesus; Instituto de Investigaciones Químicas, Química Bio-orgánica</p> <p>Lortat-Jacob, Hugues; Institut de biologie structurale, gagophile;</p> <p>Garcia-Jimenez, M. Jose; Instituto de Investigaciones Químicas, Química Bioorgánica, Glycosystems Lab.</p>
Key Words:	Glycosaminoglycan, Heparin, FGF-1, SPR, protein-carbohydrate interaction

1
2
3
4 **Importance of the polarity of the glycosaminoglycan chain on the**
5
6 **interaction with FGF-1**
7
8
9

10
11
12 **Juan C. Muñoz-García,^[a] M. José García-Jiménez,^[a] Paula Carrero,^[a] Ángeles**
13 **Canales,^[b] Jesús Jiménez-Barbero,^[b] Manuel Martín-Lomas,^[c] Anne Imberty,^[d] José L.**
14 **de Paz,^[a] Jesús Angulo,^[a] Hugues Lortat-Jacob,^[e] and Pedro M. Nieto*^[a]**
15
16
17
18
19

20
21 a) Instituto de Investigaciones Químicas, CSIC, Américo Vespucio, 49, 41092 Sevilla, Spain
22

23
24 b) Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu 9, Madrid 28040, Spain
25

26
27 c) CIC biomaGUNE, Biofunctional Nanomaterials Unit, San Sebastian 20009, Spain
28

29
30 d) CERMAV-CNRS, BP 53, 38041 Grenoble, cedex 9, France
31

32
33 e) Institute de Biologie Structural Jean Pierre Ebel, CNRS 41 rue Jules Horowitz, F-38027 Grenoble Cedex 1,
34 France
35

36
37 Phone (+) 34 954 489568, Fax: (+)34 954 460565, e-mail: pedro.nieto@iiq.csic.es
38

39
40 **Keywords:** Heparin, Glycosaminoglycan, FGF-1, protein-carbohydrate interaction, SPR
41

42
43
44 Word counting: 4173
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:

Heparin-like saccharides play an essential role in binding to the FGF-1 and to their membrane receptors FGFR forming a ternary complex that is responsible of the internalization of the signal, via the dimerization of the intracellular regions of the receptor. In this study we report the binding affinities between five synthetic hexasaccharides with human FGF-1 obtained by Surface Resonance Plasmon (SPR) experiments, and compare with the induced mitogenic activity previously obtained. These five oligosaccharides differ in the sulphation pattern and in the sequence. We have previously demonstrated that all the five hexasaccharides have similar 3D structure of the backbone. Consequently, the differences in binding affinity should have their origin in the substitution pattern. Subsequently, the different capacity for induction of mitogenic activity can be, at least partially, explained from these binding affinities. Interestingly, one of the oligosaccharides lacking of axially symmetry (**3**) was biologically inactive whereas the other (**2**) was the most active. The difference between both compounds is the order of the FGF binding motifs along the chain relative to the carbohydrate polarity. We can conclude that the directionality of the GAG chain is essential for the binding and subsequent activation. The relative biological activity of the compounds with regular substitution pattern can be inferred from their values of IC_{50} . Remarkably, the sulphate in position 6 of *D*-Glucosamine was essential for the mitogenic activity but not for the interaction with FGF-1.

Introduction

FGF-1 is a member of the Fibroblast Growth Factor family that interacts with heparin/heparan sulphate (Hep/HS) polysaccharides and the membrane receptors FGFRs. The formation of a ternary complex between FGF, FGFR and Hep/HS is the key step for the activation of the FGF signalling pathway. This is at the origin of different cellular essential functions as regulation of embryonic development, homeostasis and regenerative processes (Bernfield M et al. 1999, Eswarakumar VP et al. 2005, Kreuger J et al. 2006). Dimerization of the receptors and subsequent intracellular autophosphorylation activates a mitogenic response through an enzymatic cascade (Mohammadi M et al. 2005, Pellegrini L et al. 2000, Schlessinger J et al. 2000).

The helical structure of heparin, a highly sulphated form of HS, directs the sulphate groups towards opposite sides of its longitudinal molecular axis (Mulloy B et al. 1993). According to that, the first crystallographic structures of the heparin and human FGF-1 complexes (pdb code: 1amx and 2amx) corresponded to dimeric structures linked by a regular heparin chain in its native helical structure (DiGabriele AD et al. 1998). However, NMR data in solution corresponded to a 1:1 complex (pdb code: 2erm) (Canales A et al. 2006). Remarkably, the dimers have two alternative symmetry relationships: while for 1amx the FGF-1 proteins are related by a centre of symmetry, in the case of 2amx, the symmetry element is a plane along the binding site (DiGabriele AD et al. 1998). In addition, the ternary complexes of heparin and FGF with the extracellular domains of the membrane receptor FGFR are assembled into two different forms (pdb codes 1fq9 and 1e0o respectively) (Schlessinger J et al. 2000)(Pellegrini L 2001, Pellegrini L et al. 2000)

The analysis of these structures indicates that the Hep/HS binding site corresponds to a shallow depression on the surface of the growth factor that could be considered divided into two sub-binding sites (Digabriele AD et al. 1998). Consequently, as heparin does not much change its helical 3D structure upon binding, in the monomeric case as is the NMR complex (pdb code: 2erm)(Canales A et al. 2006) some of its sulfamate groups will be directed towards the solvent and will not interact with the FGF-1, as the structural studies have shown.

In order to analyse the heparin-FGF-1 binding mode, **2**, a hexasaccharide with axially non-symmetric sulphate groups distribution and unable to form FGF dimers was prepared (Ojeda R et al. 2002). The FGF-1 induced mitogenic activity of hexasaccharide **2** was higher than **1** (de Paz JL et al. 2001), which corresponds to the regular sulphation pattern of heparin (Angulo J et al. 2004) similar to the recently isolated from natural

1
2
3 sources as hexamer (Smits N et al. 2010). This result permitted to discard the dimerization of FGF-1 through a
4 chain of bound heparin as a requirement for the FGF-1 mediated bioactivity. Interestingly, **3**, which presents
5 similar symmetry on the sulphate groups distribution than **2**, with respect to the longitudinal axis, was inactive
6 (de Paz JL et al. 2005). The substitution pattern of **3** was designed to fit with the requisites proposed by
7 Pellegrini to maximise the interactions and symmetry in the ternary complex as it was deduced from the analysis
8 of different crystallographic structures (Pellegrini L 2001). Other synthetic oligosaccharides with diverse
9 sulfation patterns prepared in our group lacking of sulphate groups in all the positions 6-*O* of glucosamines (**4**)
10 or in all the 2-*O* of iduronates (**4**) were also inactive (Lucas R et al. 2003). During the revision of this manuscript
11 a paper describing the synthesis of three hexasaccharides and examining their bioaffinities profiles for was
12 published (Roy S et al. 2014).
13
14
15
16
17
18
19
20
21

22 Recently performed was an in depth analysis of the three-dimensional structure of **3** using NMR and MD in
23 order to search for any structural differences that might justify the loss of activity (Munoz-Garcia JC et al. 2013).
24 From this analysis it was concluded that **3** exhibits the same main structural features characteristics of heparin
25 than the analogues **1** and **2**, which are known to promote the interaction with FGF-1; a) a well-defined rigid
26 helical backbone with four residues per turn, b) a characteristic chair ¹C₄ - skew boat ²S₀ conformational
27 equilibrium for the iduronate residues, and c) a rigid behaviour of the glycosidic linkages. This structural
28 analysis allows to discard any potential difference in the three-dimensional structure that could justify the
29 differences in the observed biological activity between **2** and **3** (e.g. modification of the glycosidic linkages
30 geometry towards an *anti* disposition) (Munoz-Garcia JC et al. 2013). Consequently, the main differences in
31 affinity to FGF-1 among the hexasaccharides **1-5** would be due to the capacity of each sulfonate pattern to
32 interact with FGF-1 as a function of its spatial distribution along the chain.
33
34
35
36
37
38
39
40
41
42

43 Results

44
45
46 To investigate the ability of the five synthetic oligosaccharides, **1 – 5**, to interact with human FGF-1, an
47 inhibition assay was set up. The growth factor, either alone or coincubated with each of the five molecules to be
48 analysed, was injected over both a heparin-functionalized sensor chip and a streptavidin sensor chip, the latter
49 being used as a control surface, and the interaction was followed by Surface Plasmon Resonance (SPR)
50 spectroscopy (Figure 2). Injection of 8.8 nM of FGF-1 over the heparin surface produced a binding response of
51 350 response units (RU) at equilibrium whereas a response of 5 RU was observed over the streptavidin surface
52 (data not shown). Analysis of the results showed that these oligosaccharides strongly differ in their ability to
53
54
55
56
57
58
59
60

1
2
3 prevent FGF-1-Hep binding (Figure 2). The inhibitory activity of **1** was characterized by an IC_{50} of $8.3 \cdot 10^{-8}$ M
4
5 whereas **5** did not display binding activity in the range of concentrations tested indicating that, 2-*O* sulphate
6
7 groups were essential for the interaction (Angulo J et al. 2004). In contrast, 6-*O* sulphate groups, that are
8
9 involved in the biological activity (Angulo J et al. 2004), seem to be dispensable for the interaction with FGF-1,
10
11 with an $IC_{50} = 4.7 \cdot 10^{-7}$ M for **4**.

12
13 Next, to investigate the importance of the presentation of the sulfonate groups along the chain, the same
14
15 assay was used with **2** and **3** since both have an asymmetric sulphate distribution. Interestingly, it was observed
16
17 that, **2** features an $IC_{50} = 4.6 \cdot 10^{-7}$ M, thus similar to **4**, although **2** has five sulphate groups compared to six for
18
19 the regular oligosaccharide. Finally, **3**, which also displays six sulphate groups with an axially asymmetric
20
21 distribution, has a much lower binding activity, with an $IC_{50} = 1.6 \cdot 10^{-6}$ M. Thus, while the mitogenic activity
22
23 previously obtained was $2 > 1 \gg 3, 4, 5$ (Angulo J et al. 2004), in the case of the binding affinity the order was 1
24
25 $> 2, 4 \gg 3 \gg 5$.

26 27 Discussion

28
29 Assuming a fundamental role for the electrostatic interactions, and considering the structural differences
30
31 between the hexasaccharides, the sulphation pattern should be at the origin of the differences in the strength of
32
33 the interaction and therefore in the activity. Apparent inconsistencies between the larger IC_{50} values for **1**
34
35 compared with **2**, measured by SPR experiments, and the induction of mitogenic activity, which is larger for **2**,
36
37 can be explained considering the assembly of the ternary complex. This is essential for the biological activity,
38
39 and additional hidden requirements may play additional roles (Pellegrini L et al. 2000, Schlessinger J et al. 2000).

40
41 Compounds **2** and **3**, as they have their sulfonate groups directed towards one side of the molecular axis,
42
43 only can interact with FGF using one of their half. On the contrary, as the 3D-structures of **1**, **4** and **5** have an
44
45 axially symmetric distribution of sulfonate groups, they have the possibility to interact with two molecules of
46
47 FGF using two opposite sides of the oligosaccharide in a sandwich like fashion, with two simultaneous binding
48
49 events (Angulo J et al. 2004, de Paz JL et al. 2001, Lucas R et al. 2003). This observation might also explain the
50
51 observed differences between the mitogenic activity measured by proliferation studies (Angulo J et al. 2004) and
52
53 the relative binding strength to FGF-1, reported in this study.

54
55 The heparin binding site of FGF-1 could be divided into two spatially contiguous sub-sites (DiGabriele AD
56
57 et al. 1998). The first one binds a trisaccharide GlcNS – IdoA2S – GlcN6S, interacting via three negatively
58
59
60

1
2
3 charged sulphate moieties (Saxena K et al. 2010). Such arrangement of charged groups displays the proper
4 number and orientation of sulfonate groups to establish a tight interaction with FGF-1. Recent studies have
5 revealed key differences between FGF-1 and FGF-2 binding to GAG in this subsite. For the case of FGF-2 the
6 trisaccharide that interacts in subsite a is the complementary one, Ido2S – GlcNS – Ido2S (Saxena K et al. 2010).
7
8 The second sub-site interacts with a disaccharide, GlcN6S – IdoA2S. A central iduronate residue with a non-
9 participating sulfonate group links both motifs. Remarkably, hexasaccharides **2** and **3**, display simultaneously
10 these two decorations for the interaction with FGF-1 but, in reverse order if the polarity of the chain is
11 considered.
12
13
14
15
16

17
18 In an attempt to find a satisfactory explanation to the lack of activity of **3** with respect to **2**, a molecular
19 modelling docking protocol was employed to analyse the molecular interactions from a structural perspective.
20 Thus, the backbone of the most representative conformation of **3**, taken from 500 ns of unrestrained molecular
21 dynamics trajectory (Munoz-Garcia JC et al. 2013), was manually superimposed to the most representative
22 structure of the NMR complex between FGF-1 and **2** (pdb 2erm). As the distances between the three sulphate
23 groups directed towards the same side of the molecule were similar, two polarities for superimposition were used,
24 from the reducing to non-reducing end and its reversed alternative. We have employed as first criteria, the
25 alignment of the longitudinal axis of both carbohydrates. However, the positions of the sulfonate and sulfamate
26 groups of **3** were not adequate for the complete interaction with the complementary residues of the protein. After
27 that, the non-reducing end trisaccharide of **3** was manually docked into the main sub-site in the “reverse”
28 orientation. In this case, the rest of the oligosaccharide did not fit in the complete binding pocket and pointed
29 towards outside the complex. In addition, a steric clash was observed between the protein side chains and the
30 GlcN – IdoA – GlcN trisulphated trisaccharide of **3** (see Suppl. Info. for description of additional modes). The
31 impossibility to assemble a complex with the complete set of charged interactions between the FGF-1 and the
32 hexasaccharide **3**, lead us to conclude that the correct polarity of the GAG chain is essential for the interaction
33 with the growth factor (FGF-1).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 We decided to perform docking calculations in order to get a deeper insight into the possible binding of **3** and
50 FGF-1. We have used Glide, first using the Induced Fit Docking protocol with the standard conditions and then,
51 the results were subjected to a run of Single Precision Docking. In this case, the focus was put into the three
52 saccharides of the triad, leading to a displaced sequence. A remarkable superimposition of the poses for this
53 region was found in the solutions (see supplementary material).
54
55
56
57
58
59
60

1
2
3 Interestingly, **2** (Figure 3a) has both sulphate clusters in the right disposition to interact simultaneously with
4 both binding sub-sites while **3** is only capable of interacting with the sub-site a (Figure 3) (Canales A et al. 2006).
5 This can explain the value of IC_{50} for **3**, 3.5 fold larger than **2**. This difference can be explained considering that
6 the polarity of the glycosaminoglycan chain is essential for the maximum number of interactions take place.
7 While the sub-site a is interacting with **2** through the trisaccharide GlcNS – IdoS – Glc6S starting at glucosamine
8 in position i, the equivalent trisaccharide that binds the main subsite in the case of **3** is shifted to the GlcN at
9 position i+4. The secondary binding sub-site does not establish any interaction with **3**, thus explaining the lower
10 affinity measured by SPR and the absence of mitogenic activity due to the failure to assemble of higher order
11 complexes needed. Therefore, the interaction between FGF-1 and **3** should be weaker than **2**. This should be the
12 cause why **2** and **3** showed such dramatic differences in their binding affinity and bioactivity in spite of bearing
13 the same two binding motifs, but in opposite order.
14
15
16
17
18
19
20
21
22
23

24 Additional information can be extracted from the comparison between the affinity experiments and biological
25 activity ones. For instance, the sulphation in position 6 of glucosamine that, according to our previous biological
26 results, is essential for the FGF-1 mitogenic activity (Angulo J et al. 2004), it is not for the interaction with FGF-
27 1. That observation might be exploited in the design of potential inhibitors of the FGF-1 mediated mitogenic
28 activity that being able to interact with the FGF-1, the absence of this key group prevent the assembly of the
29 ternary active complex, and the subsequent biological activity. Another important conclusion that can be
30 extracted from our work is the evidence of the strong influence of the polarity of the GAG chain on the binding.
31 This also can be exploited for the design of inhibitors that interacting with the FGF-1 they do with the opposite
32 polarity and they will not be able to form the active ternary complex.
33
34
35
36
37
38
39
40
41

42 In summary, we have demonstrated that the polarity of the oligosaccharide chain relative to FGF-1 is a
43 critical factor for the strength of the binary interaction and further assembly of the ternary complex (Brown A et
44 al. 2013).
45
46
47

48 **Materials and Methods**

49
50
51 Syntheses of compounds **1 - 5** have been previously described (de Paz JL et al. 2001, de Paz JL and Martin-
52 Lomas M 2005, Lucas R et al. 2003, Ojeda R et al. 2002).
53
54

55 Size defined heparin (Hep; 6 kDa) was immobilized on a Biacore sensorchip. For that purpose, Hep was
56 biotinylated at its reducing end by coincubation with 10 mM biotin/LC-hydrazine for 24 h at room temperature.
57
58
59
60

1
2
3 The mixture was then extensively dialyzed against H₂O to remove unreacted biotin and freeze-dried. Two flow
4 cell of a CM4 sensorchip were then functionalized with approx. 2500 resonance units (RU) of streptavidin as
5 described (Crublet E et al. 2008) and biotinylated HP (5 µg/ml), in HBS-EP (10 mM HEPES, 150 mM NaCl, 3
6 mM EDTA, 0.005% surfactant P20, pH 7.4) was injected across one flow cells to obtain an immobilization level
7 of 50 RU. The other flow cell was left untreated and served as negative control. For binding assays, 150 µl of
8 FGF-1 (8.8 nM), co incubated with a range of concentration of the different oligosaccharides, were
9 simultaneously injected, at a flow rate of 50 µl/min, over the control and the HP surfaces. The formed complexes
10 were washed with running buffer for 3 min and the sensorchip surfaces were regenerated with a 3 minute pulse
11 of 2 M NaCl. Control sensorgrams were subtracted on line from HP sensorgrams.
12
13
14
15
16
17
18
19

20 The protein data bank structures 1amx, 2amx and 2erm were used for the preliminary studies of docking
21 described in this paper, performed with GLIDE (Friesner RA et al. 2004). The monomer C from the 1amx
22 complex was isolated from the rest of the aggregates and used to prepare the model of the hexasaccharide **3** with
23 FGF-1 by superimposition of the trisaccharide of its reducing end with the one at the non-reducing end of the
24 1amx and/or 2erm complexes aligning the sulfate groups. Hydrogens atoms were added to the crystallographic
25 structure when it was necessary using the Maestro protein preparation module. The corresponding hexa- and
26 pentasaccharides were prepared and named consistently and using partial charges from GLYCAM (Kirschner
27 KN et al. 2008), ligand preparation module was run and the structure was minimized. A grid (10 x 10 x 10 Å)
28 centered in the glycosaminoglycan was constructed. We first run an Induced Fit Docking with the standard
29 conditions keeping the GLYCAM charges. The resulting structures were submitted to a Single Precision
30 Docking, with a 10 Å grid using GLYCAM partial charges with an electrostatic cutoff of 2.0. The minimization
31 was performed using OPLS-2005 force field with a dielectric constant of 4r
32
33
34
35
36
37
38
39
40
41
42
43

44 Funding

45
46 This work was supported by CSIC (JAEPRe_09_01999 to J.C.M-G and 2004FR0025), Junta de
47 Andalucía (P07-FQM-02969), Spanish Ministry of Science and Innovation (CTQ2009-07168,
48 CTQ2012-32025, and CTQ2012-32605; and RYC-2007-01791 to J.A.), and the European Union
49 (FEDER).
50
51
52
53
54

55 Abbreviations

56
57
58
59
60

1
2
3 3D, Three-dimensional; FGF, Fibroblast Growth Factor; FGFR, Fibroblast Growth Factor Receptor; Hep,
4 Heparin; HS, Heparan Sulfate; MD, Molecular Dynamics; NMR; Nuclear Magnetic Resonance; RU, Response
5 Units; SPR, Surface Plasmon Resonance
6
7
8
9
10
11
12
13
14
15
16
17
18
19

20 References

21 Angulo J, Ojeda R, de Paz JL, Lucas R, Nieto PM, Lozano RM, Redondo-Horcajo M, Gimenez-Gallego G,
22 Martin-Lomas M. 2004. The activation of fibroblast growth factors (FGFs) by glycosaminoglycans: Influence of
23 the sulfation pattern on the biological activity of FGF-1. *ChemBioChem*. 5: 55-61.
24
25

26
27
28 Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface
29 heparan sulfate proteoglycans. *Annu. Rev. Biochem.* 68: 729-777.
30
31

32
33 Brown A, Robinson CJ, Gallagher JT, Blundell TL. 2013. Cooperative Heparin-Mediated Oligomerization of
34 Fibroblast Growth Factor-1 (FGF1) Precedes Recruitment of FGFR2 to Ternary Complexes. *Biophys. J.* 104:
35 1720-1730.
36
37

38
39 Canales A, Lozano R, Lopez-Mendez B, Angulo J, Ojeda R, Nieto PM, Martin-Lomas M, Gimenez-Gallego G,
40 Jimenez-Barbero J. 2006. Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide
41 heparin-analogue. *FEBS J.* 273: 4716-4727.
42
43
44

45
46 Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H. 2008. The HIV-1 envelope glycoprotein gp120 features four
47 heparan sulfate binding domains, including the co-receptor binding site. *J. Biol. Chem.* 283: 15193-15200.
48
49

50
51 de Paz JL, Angulo J, Lassaletta JM, Nieto PM, Redondo-Horcajo M, Lozano RM, Gimenez-Gallego G, Martin-
52 Lomas M. 2001. The activation of fibroblast growth factors by heparin: Synthesis, structure, and biological
53 activity of heparin-like oligosaccharides. *ChemBioChem*. 2: 673-685.
54
55
56
57
58
59
60

1
2
3 de Paz JL, Martin-Lomas M. 2005. Synthesis and biological evaluation of a heparin-like hexasaccharide with the
4 structural motifs for binding to FGF and FGFR. *Eur. J. Org. Chem.* 1849-1858.

6
7 DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, Hendrickson WA. 1998. Structure of a
8 heparin-linked biologically active dimer of fibroblast growth factor. *Nature.* 393: 812-817.

10
11 Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. *Cytokine*
12 *Growth Factor Rev.* 16: 139-149.

14
15 Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M,
16 Perry JK, *et al.* 2004. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and
17 Assessment of Docking Accuracy. *J. Med. Chem.* 47: 1739-1749.

19
20 Kirschner KN, Yongye AB, Tschampel SM, González-Outeiriño J, Daniels CR, Foley BL, Woods RJ. 2008.
21 GLYCAM06: A generalizable biomolecular force field. *carbohydrates. J. Comput. Chem.* 29: 622-655.

23
24 Kreuger J, Spillmann D, Li JP, Lindahl U. 2006. Interactions between heparan sulfate and proteins: the concept
25 of specificity. *J. Cell Biol.* 174: 323-327.

27
28 Lucas R, Angulo J, Nieto PM, Martin-Lomas M. 2003. Synthesis and structural study of two new heparin-like
29 hexasaccharides. *Org. Biomol. Chem.* 1: 2253-2266.

31
32 Mohammadi M, Olsen SK, Ibrahimi OA. 2005. Structural basis for fibroblast growth factor receptor activation.
33 *Cytokine Growth Factor Rev.* 16: 107-137.

35
36 Mulloy B, Forster MJ, Jones C, Davies DB. 1993. Nmr and Molecular-Modeling Studies of the Solution
37 Conformation of Heparin. *Biochem. J.* 293: 849-858.

39
40 Munoz-Garcia JC, Solera C, Carrero P, de Paz JL, Angulo J, Nieto PM. 2013. 3D structure of a heparin mimetic
41 analogue of a FGF-1 activator. A NMR and molecular modelling study. *Org. Biomol. Chem.* 11: 8269-8275.

43
44 Ojeda R, Angulo J, Nieto PM, Martin-Lomas M. 2002. The activation of fibroblast growth factors by heparin:
45 Synthesis and structural study of rationally modified heparin-like oligosaccharides. *Can. J. Chem.-Rev. Can.*
46 *Chim.* 80: 917-936.

47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Pellegrini L. 2001. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. *Curr. Opin.*
4
5 *Struct. Biol.* 11: 629-634.

6
7 Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. 2000. Crystal structure of fibroblast growth factor
8
9 receptor ectodomain bound to ligand and heparin. *Nature.* 407: 1029-1034.

10
11 Roy S, El Hadri A, Richard S, Denis F, Holte K, Duffner J, Yu F, Galcheva-Gargova Z, Capila I, Schultes B, *et*
12
13 *al.* 2014. Synthesis and Biological Evaluation of a Unique Heparin Mimetic Hexasaccharide for Structure-
14
15 Activity Relationship Studies. *J. Med. Chem.*

16
17 Saxena K, Schieborr U, Anderka O, Duchardt-Ferner E, Elshorst B, Gande SL, Janzon J, Kudlinzki D,
18
19 Sreeramulu S, Dreyer MK, *et al.* 2010. Influence of Heparin Mimetics on Assembly of the FGF-FGFR4
20
21 Signaling Complex. *J. Biol. Chem.* 285: 26628-26640.

22
23 Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M.
24
25 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding
26
27 and dimerization. *Mol. Cell.* 6: 743-750.


28
29 Smits N, Kurup S, Rops A, ten Dam G, Massuger L, Hafmans T, Turnbull J, Spillmann D, Li J-p, Kennel S, *et al.*
30
31 2010. The heparan sulfate motif (GlcNS6S-IdoA2S)₃, common in heparin, has a strict topography and is
32
33 involved in cell behavior and disease. *J. Biol. Chem.* 285: 41143-41151.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to Figures


1
2
3
4
5
6
7
8
9 **Figure 1.** Heparin hexasaccharides analysed in this work in planar representation showing the relative
10 disposition of the sulphate groups according to the 3D structure of heparin (PDB code 1hpn).
11

12
13
14 **Figure 2.** Inhibition of the FGF-1-HEP interaction by synthetic oligosaccharides. FGF-1 (8.8 nM) was
15 preincubated with a range of concentrations of the different oligosaccharides and injected for 3 min over a HEP-
16 activated sensor chip at 50 $\mu\text{L}/\text{min}$ (see Suppl. Info.). The binding responses (in RU) were recorded as a function
17 of time and corresponded to the FGF-1-HEP complexes in presence of **1** (A), **2** (B), **3** (C), **4** (D) and **5** (E). The
18 oligosaccharide concentrations were (from top to bottom curves in each panel) 0, 0.0055, 0.0165, 0.15, 0.5, 1.33
19 and 4 μM .
20
21
22
23
24
25
26
27


28 **Figure 3.** Top, representation of the binding modes relatives to the binding subsites on FGF-1 of **2** (red) and **3**
29 (yellow); the non-reducing is at the left. Superimposition of the NMR structure of human FGF-1 with
30 hexasaccharide **2** (red; pdb code 2erm) and model constructed by docking for hexasaccharide **3** (yellow).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1




2



3




4



5

123x148mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





46x7mm (300 x 300 DPI)

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



293x305mm (300 x 300 DPI)